"At this juncture, the relatively small $15 billion company has some big-name investors behind it, including the likes of Ark Invest's Cathie Wood, as well as Congresswoman Nancy Pelosi, who picked up a considerable amount of shares at the start of the year. While following the smart money into the choppy, high-growth mid-cap stocks may be met with mixed results, I must say that Tempus AI is an exciting name that's shown early glimmers of potential."
"Of course, investing in such hyper-growth companies entails taking on more risk, but if you're a believer that we're shifting hype from large language model (LLM) makers and AI infrastructure companies (where the puck is currently at right now) and towards applied AI as models become better tailored for specific use cases, Tempus AI stock is a name for the top of your radar."
Tempus AI is a roughly $15 billion company focused on applying machine learning to healthcare and biotech. The company attracts notable investors including Ark Invest and private investors such as Nancy Pelosi. Health AI is highlighted as a potentially transformative area where models address difficult medical problems and create applied-use cases beyond generative AI. Investing in hyper-growth, mid-cap health AI firms carries elevated risk but may reward investors if AI shifts from general LLMs and infrastructure toward tailored medical solutions. Recent share-price declines have reduced valuation and may create a buying opportunity for risk-tolerant investors.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]